AstraZeneca’s BAXFENDY™ (baxdrostat) has been approved in the US as a first-in-class aldosterone synthase inhibitor (ASI) for the treatment of hypertension in combination with other antihypertensive ...

AstraZeneca AZN announced that the FDA has approved baxdrostat for treating adult patients with uncontrolled or ...

The FDA’s recent approval of baxdrostat may usher in new possibilities for treatment for uncontrolled hypertension.

A new blood pressure medication has been approved in the U.S., but this one isn’t quite like others that help treat ...

When you think of high blood pressure, lifestyle choices around nutrition or exercise may come to mind—not your hormones. But ...

The FDA approved the first-in-class oral aldosterone synthase inhibitor baxdrostat (Baxfendy) to treat adults with ...

A drug that has been used to slow progression of kidney and cardiovascular disease in people with type 2 diabetes may also help people with chronic kidney disease who do not have diabetes, according ...

A steroid hormone called aldosterone is linked to an increased risk of kidney failure in patients with chronic kidney disease (CKD), according to a study published in the European Heart Journal today ...

Please provide your email address to receive an email when new articles are posted on . Aldosterone is associated with an increased risk of chronic kidney disease progression and the development of ...

Purpose: The clinical benefits, adverse effects, pharmacokinetics, and recommendations for the appropriate use of the aldosterone antagonists spironolactone and eplerenone in patients with heart ...

Lorundrostat, a novel therapy which blocks the production of aldosterone from the adrenal glands, demonstrated clinically meaningful and sustained reductions in blood pressure in 1,083 patients with ...

Participants were invited to attend a clinical visit with blood sampling and physical examination in 1995/1996 (baseline) and 2001/2002 (mean follow-up=5.4±0.3 years). The number of participants at ...